

**2<sup>nd</sup> EDITION Update on Diabetes and CVD** 

Meeting in cooperation between:

D&CVD Study Group

(Reference Study Group of EASD)
IRCCS MultiMedica, Milan
University of Campania
"Luigi Vanvitelli"

17<sup>th</sup>-18<sup>th</sup> January 2025

NAPLES Hotel Royal Continental





### **SCIENTIFIC RATIONALE**

The presence of hyperglycemia associated with the well-known risk factors of metabolic syndrome and diabetes itself predisposes to important cardiovascular complications which strongly impact not only the patient's quality of life, but, more generally, the entire community, also from an economic point of view. The cardio-vascular-renal complications of diabetes still represent the major cause of mortality and disability, resulting in hospital admission in over 75% of cases.

In recent years, different categories of drugs with proven positive effects determining a significant cardiovascular and renal event reduction have been recommended in national and international guidelines, for the early treatment of diabetes. It is of the utmost importance to assess cardiovascular risk in individuals with diabetes who do not have clinical evidence of cardiovascular disease yet, in order to identify those at the highest risk. For these patients maximum prevention must has to be immediately activated, including lifestyles modifications and the implementation of the most appropriate therapy.

From stratification of cardiovascular risk to screening, diagnosis and treatment.

The new Guidelines of the European Society of Cardiology (ESC), for cardiovascular diseases, in people with diabetes, evaluate and summarize the available scientific evidence, with the aim of supporting health professionals in proposing the best diagnostic and therapeutic approach.

The purpose of this course is therefore to deepen and update the current knowledge about the prevention of diabetes complications, taking advantage of the maximum interaction between cardiologists and diabetologists. Further goals are to deepening the epidemiology and the pathogenesis of renal and cardiovascular diseases, the beneficial effects of prevention, the comparison of the different therapeutic approaches and the possible advantages of an earlier and more generalized use.



# **2<sup>nd</sup> EDITION Update on Diabetes and CVD**

## Meeting in cooperation between: D&CVD Study Group

(Reference Study Group of EASD)

IRCCS MultiMedica, Milan

University of Campania "Luigi Vanvitelli"

### **Scientific Directors**

Cesare Celeste Federico Berra Antonio Ceriello Paola Muti Giuseppe Paolisso

#### **INVITED FACULTY**

Tadej Battelino, Ljubljana (SI)
Cesare Berra, Milan (IT)
Federico Bertuzzi, Milan (IT)
Raffaella Buzzetti, Rome (IT)
Paolo Calabrò, Naples (IT)
Riccardo Candido, Trieste (IT)
Antonio Ceriello, Barcelona (ES)
Annamaria Colao, Naples (IT)
Caterina Conte, Rome (IT)
Salvatore De Cosmo, Bari (IT)
Giovanni Esposito, Naples (IT)
Katherine Esposito, Naples (IT)
Amalia Gastaldelli, Siena (IT)

Francesco Giorgino, Bari (IT)
Paolo Golino, Naples (IT)
Per-Henrik Groop, Helsinki (FI)
Didac Mauricio, Catalonia (ES)
Ciro Mauro, Naples (IT)
Barbara Mcgowan, London (UK)
Paola Muti, Milan (IT)
Giovanni Francesco Nicoletti, Naples (IT)
Mark Nieuwenhuijsen, Barcelona (ES)
Emanuela Orsi, Milan (IT)
Giuseppe Paolisso, Naples (IT)
Pasquale Perrone Filardi, Naples (IT)
Paola Ponzani, Chiavari, GE (IT)

Francesco Prattichizzo, Milan (IT)
Giuseppe Pugliese, Rome (IT)
Giuseppe Rosano, London (IT)
Peter Rossing, Copenhagen (DK)
Giuseppina Russo, Messina (IT)
Ferdinando Carlo Sasso, Naples (IT)
Peter Schwarz, Dresden (DE)
Samuel Seidu, Leicester (UK)
Paul Valensi, Aubervilliers (FR)
Luc Van Gaal, Antwerp (BE)
Michal Vrablik, Prague (CZ)

## **DAY 1: JANUARY 17th 2025**

09.00-09.20 Welcome and introduction to the meeting Antonio Ceriello (Chair D&CVD Study Group) Paola Muti (Scientific Director IRCCS MultiMedica) Gianfranco Nicoletti (Rector - University of Campania "Luigi Vanvitelli") Giuseppe Paolisso (Vanvitelli University) 09.20-09.30 Aim of the meeting	12.00-12.15 12:15-12:30	Weight management and possible side effects Chair: Annamaria Colao Weight management in obesity Luc Van Gaal Weight management in type 2 diabetes Katherine Esposito
Cesare Berra (IRCCS Multimedica)  09,30-10,30 Environment and diabetes		Weight management in type 1 diabetes Francesco Bertuzzi
Chairmen: Antonio Ceriello,	12.45-13.00	Discussion
Ciro Mauro 09.30-09.45 Air pollution exposure and cardiometabolic risk		Cardio-renal disease in type 2 diabetes Chair: Paolo Calabrò
Mark Nieuwenhuijsen 09.45-10.00 Micro and nanoplastics and CVD Giuseppe Paolisso	13.00-13.15	How cardiologists can manage excess body weight and related cardiovascular risk Pasquale Perrone Filardi
10.00-10.15 <b>Micro and nanoplastics and CVD in diabetes</b> Francesco Prattichizzo		The link between heart failure and kidney disease: how to face diabetes?  A cardiologist point of view - Giuseppe Rosano
10.15-10.30 <b>Discussion</b> 10.30-11.30 <b>Cardio-renal disease in type 1 diabetes</b> Chair: Salvatore De Cosmo	13.30-13.45	The link between heart failure and kidney disease: how to face diabetes?  A diabetologist point of view - Paul Valensi
10.30-10.45 <b>CVD in type 1 diabetes</b> Didac Mauricio		Discussion
10.45-11.00 <b>CKD in type 1 diabetes</b> Per-Henrik Groop	15.00-16.00	<b>Lectures</b> Chairmen: Antonio Ceriello, Giuseppe Paolisso
11.00-11.15 <b>New therapeutic perspective</b> Peter Rossing	15.00-15.30	The reality of diabetes prevention Peter Schwarz
11.15-11.30 <b>Discussion</b> 11.30-12.00 <i>Coffee Break</i>	15.30-16.00	The link between diabetes, cancer and CVD Paola Muti

	Cardio-renal disease in type 2 diabetes Chair: Giovanni Esposito	16.30-16.45	The RIACE trial Giuseppe Pugliese
16.00-16.15	'		From CVOT to guidelines: the value of SGLT2-i in prevention and treatment of MTC2 C. Berra
16.15-16.30	MASLD/NASH and CVD Amalia Gastaldelli	18.00-18.15 18.15	Discussion End of day one

## **DAY 2: JANUARY 18th 2025**

09.00-10.00	What's new on devices e monitoring in type	11.00-11.30	Coffee Break
	2 diabetes Chair: Emanuela Orsi	11.30-11.50	Bempedoic Acid Michal Vrablik
09.00-09.15	How can CGM help? Tadej Battelino	11.50-12.10	iPCSK9 and cardiovascular risk control in patients at high risk
09.15-09.30	Platforms and devices: how can help in type		Francesco Bandera
	2 diabetes Paola Ponzani	12.10 -12.30	Discussion
09.30-09.45	Adherence and technology: new possibility for old problems	12.30-13.30	New perspectives Chair: Ferdinando Carlo Sasso
	Caterina Conte	12.30-12.45	New insulins
09.45-10.00	Discussion		Cesare Berra
10.00-11.00	Clinical inertia Chair: Raffaella Buzzetti	12.45-13.00	New therapies for the treatment of diabetes and obesity  Barbara McGowan
10.00-10.15	<b>Defining clinical inertia</b> Samuel Seidu	13.15-13.30	How early should be the use of SGLT-2i and GLP-1RA?
10.15-10.30	The situation in Italy Riccardo Candido		Giuseppina Russo
10.30-10.45	Is starting with more drugs the solution? Francesco Giorgino	13:45-14:00	
10.45-11.00	Discussion	14:00	End of meeting

### DATE

17th-18th January 2025

## **VENUE**

Hotel Royal Continental
Via Partenope, 38 - 80121 Naples

### **ORGANIZING SECRETARIAT & CME PROVIDER - 181**



PROVIDER CME STANDARD accredited by the National Commission for Continuing Medical Education of the Ministry of Health with number 181.

MIND DISTRICT-The Hive/H2-Viale Decumano 36, 20157 Milano giada.giuliani@dynamicom-education.it



The meeting is accredited for the Italian physicians, in accordance with the existing national laws on CME.

Profession: Physicians and Nurse Reserved to the following categories:

Metabolic Diseases and Diabetology, Endocrinology,

Cardiology, Geriatrics, Internal Medicine.

Number of participants: 200 Training objective: n. 3 Assigned CME credits:

Official meeting languages: Italian and English

## **2<sup>nd</sup> EDITION Update on Diabetes and CVD**

D&CVD

## Meeting in cooperation between: D&CVD Study Group

(Reference Study Group of EASD) IRCCS MultiMedica, Milan University of Campania "Luigi Vanvitelli"

With the unconditional support of:

ABBOTT
AMGEN
ASTRAZENECA
AURORA BIOFARMA
BAYER AG
BRUNO FARMACEUTICI
ELI LILLY
NOVO NORDISK

Thanks to the following sponsor companies for the printing:







